Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The mechanistic target of rapamycin (mTOR) pathway is frequently deregulated in glioblastoma (GBM), a deadly brain tumor.
• Despite advancements, GBM treatments remain largely ineffective, with poor survival rates.
• The PTEN/PI3K/AKT/mTOR pathway is critical for GBM development and progression.

Purpose of the Study:

• To review the rationale for targeting the mTOR pathway in GBM.
• To analyze preclinical and clinical evidence for mTOR-targeted therapies in GBM.
• To highlight the distinct roles of mTORC1 and mTORC2 in GBM biology.

Main Methods:

• Literature review of preclinical studies.
• Analysis of clinical trial data.
• Examination of molecular mechanisms of mTOR signaling in GBM.

Main Results:

• Inhibitors targeting PI3K, AKT, or mTORC1 have not improved GBM patient outcomes.
• Emerging evidence suggests that blocking mTORC2 may be a viable therapeutic strategy for GBM.
• mTORC1 and mTORC2 play different roles in GBM, necessitating distinct therapeutic approaches.

Conclusions:

• Targeting the mTOR pathway remains a key area for GBM therapeutic development.
• mTORC2 inhibition presents a potential strategy to overcome limitations of previous mTORC1-targeting attempts in GBM.
• Further research into the specific roles of mTORC1 and mTORC2 is essential for optimizing GBM treatment.